What are the functions and efficacy of resmetirom?

Resmetirom - Rezdiffra is a new oral drug that has attracted much attention in recent years. It is mainly used to treat adult patients with non-alcoholic steatohepatitis (NASH) combined with moderate to severe liver fibrosis. Its mechanism of action is different from traditional lipid-lowering drugs or drugs that simply improve metabolism. It is a thyroid hormone receptor beta (THR-β) selective agonist that reduces liver fat accumulation by targeting the liver metabolic pathway, and delays or even reverses the progression of liver fibrosis. This makes it a landmark in the treatment landscape of NASH.

In clinical practice,NASH is a metabolic disease highly related to obesity, diabetes, and hyperlipidemia, and its long-term development may lead to cirrhosis and even liver cancer. Resimeterol can reduce fat deposition in the liver by regulating cholesterol metabolism, improving lipid profiles, and thereby reducing inflammation and fibrosis. Compared with common life interventions, this targeted drug provides patients with a more direct medical intervention.

In addition to improving the structure and function of the liver, overseas research data shows that resmetirol also shows positive effects in reducing serum low-density lipoprotein cholesterol (LDL-C), and has potential dual benefits for patients with NASH combined with high cardiovascular risk factors. This metabolic improvement not only aids in the long-term management of liver disease but also reduces overall cardiovascular risk.

Currently, resmetirol is recommended to be used in combination with diet control and regular exercise to avoid relying solely on drugs and neglecting lifestyle intervention. As the drug is gradually approved in many countries, it is expected to become an important basic drug in the treatment of NASH, bringing new hope to a large number of patients who lack effective treatments.

Reference materials:https://www.drugs.com/monograph/resmetirom.html